New Jersey

Overview

New Jersey legalized medical cannabis in 2010 via the Compassionate Use Medical Marijuana Act, and adult-use cannabis in 2020 via Public Question 1 (passed 67%-33%). The enabling adult-use statute is the Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act (CREAMMA), which was signed February 22, 2021. Licensed adult-use retail sales began April 21, 2022, and the market exceeded $1 billion in cumulative sales by 2024.

Both programs are administered by the Cannabis Regulatory Commission (CRC).

Adult-use (CREAMMA, 2021)

• Public possession: up to 6 oz of cannabis or equivalent.
• Per-transaction purchase: 1 oz flower, 5 g concentrate, 1,000 mg total THC in edibles.
• Home cultivation: prohibited. For both adult-use and medical patients. Multiple bills (S 2564, S 1758) have been introduced to authorize patient and adult home cultivation; none have reached a floor vote.
• Public consumption: prohibited on federal lands, beaches, parks, and any indoor public space where tobacco smoking is banned. Functionally restricts adult-use cannabis to private residences.

Medical program

Qualifying conditions

The Compassionate Use Medical Marijuana Act enumerates a substantial qualifying-condition list that includes:

• Cancer, HIV/AIDS, ALS, multiple sclerosis, muscular dystrophy
• Inflammatory bowel disease (Crohn's, ulcerative colitis)
• Seizure disorders / epilepsy
• Glaucoma
• PTSD
• Chronic pain (anxiety, migraine, opioid use disorder, and other expansions added by CRC rulemaking)
• Terminal illness (with no possession cap)

Patient access

• Possession: up to 3 oz per 30-day supply for non-terminal patients; no cap for terminal-illness patients.
• Approved forms: flower, oils, edibles, vapes, topicals, tinctures.
• Home cultivation for patients: prohibited (same as adult-use).
• Reciprocity: New Jersey does not formally recognize out-of-state medical cards for in-state medical-cannabis preferential pricing; out-of-state patients aged 21+ may purchase from any adult-use retailer.

Patients and caregivers

• Patient minimum age: no statutory floor. Minor patients require a designated caregiver and physician certification.
• Caregiver minimum age: 18. (NJ permits younger caregivers than most states: verify against current CRC rules.)
• Caregivers per patient: up to 2 designated caregivers per patient (verify with CRC).
• Caregiver registration: via the CRC; criminal background check; cannot consume the patient's cannabis unless also a registered patient.

Patient registration steps

1. Schedule a visit with a New Jersey-licensed physician, APRN, or PA who is registered with the CRC as authorized to recommend medicinal cannabis. The provider must establish a bona fide patient-provider relationship.
2. The provider issues an Authorization through the CRC Medicinal Cannabis Program portal.
3. The patient completes the registry application, submits identity documents, proof of New Jersey residency, and a current photo. The standard registration fee is $10 (one of the lowest in the country); reduced fees apply for veterans, seniors, and patients on Medicaid or SNAP.
4. Approved patients receive a CRC patient ID that authorizes purchases from any New Jersey Alternative Treatment Center (ATC) under medical-program pricing and product-form rules.

Minor patients require a designated caregiver and a second physician's concurring certification. The caregiver completes a separate application and New Jersey State Police background check.

Reciprocity and visiting patients

New Jersey's framework is dual-track for visitors:

• Adult-use: any visitor 21 or older with a government-issued photo ID may purchase from a licensed adult-use retailer under the 1 oz / 5 g / 1,000 mg per-transaction caps.
• Medical: New Jersey does not formally recognize out-of-state medical cards for medical-program preferential pricing. Visiting medical patients access cannabis through the adult-use retail framework if 21 or older.

The medical-program tax preference (no sales tax on medical cannabis) is significant for high-volume patients. Visiting medical patients cannot access this preference or the higher 3 oz / 30-day medical possession cap.

Employment and workplace

New Jersey provides notable employment protections under CREAMMA, with carve-outs:

• Adverse action restriction: CREAMMA prohibits employers from taking adverse employment action against an employee solely because of the employee's cannabis use or a positive cannabis test result, subject to specific exceptions.
• Workplace impairment: employers may still discipline employees for on-the-job impairment as reasonably documented. The CRC has developed Workplace Impairment Recognition Expert (WIRE) standards (implementation has lagged).
• Federal contractor and DOT-regulated positions: federal drug-free workplace and DOT testing rules supersede state-level protection.
• Safety-sensitive positions: narrower carve-out than in most states; employers must specifically establish on-the-job impairment.
• Workers' compensation: post-incident testing positive for THC may affect benefits if impairment at the time of incident is established.

New Jersey's CREAMMA employment-protection framework is among the more worker-favorable in the United States. The WIRE certification pathway has been the implementation bottleneck.

Hemp-derived intoxicants

New Jersey enacted comprehensive restrictions on hemp-derived intoxicating cannabinoids through legislation in 2024 (effective 2025), placing delta-8 THC, delta-10 THC, THC-O, and HHC products under the CRC's regulatory authority. Outside the licensed adult-use and medical-cannabis supply chain, these products are not lawful for retail sale to consumers.

Recent legislative and regulatory history

Notable post-2021 developments:

• 2010: Compassionate Use Medical Marijuana Act enacted.
• 2020: Public Question 1 (constitutional adult-use legalization) approved.
• 2021: CREAMMA signed February 22; CRC established.
• 2022: licensed adult-use retail sales began April 21.
• 2023: ATC conversion pathway broadened; first wave of standalone adult-use retail licensees opened.
• 2024: market exceeded $1 billion in cumulative sales; hemp-derived intoxicant restrictions enacted.
• 2025-2026: continued legislative work on home cultivation (S 2564 / S 1758 series), on-premises consumption pilots, and expungement implementation.

The April 2026 federal Schedule III rescheduling order produced no immediate New Jersey legislative response.

Expungement

New Jersey established a substantial expungement framework alongside legalization. Many low-level cannabis convictions have been automatically vacated or sealed under post-2020 amendments to N.J.S.A. 2C:52, including some convictions that pre-date the Compassionate Use Act. Implementation has been carried out by the New Jersey Judiciary with limited application requirement from affected individuals.

Federal context

Federal jurisdiction layers additional exposure on federal land, federal courthouses, military installations (Joint Base McGuire-Dix-Lakehurst, Naval Weapons Station Earle, Picatinny Arsenal, Coast Guard Training Center Cape May), and interstate highways. Gateway National Recreation Area, Delaware Water Gap National Recreation Area, and several Federal Aviation Administration facilities fall under federal jurisdiction where cannabis prohibition applies. I-78, I-80, I-95 (NJ Turnpike), I-280, and the Garden State Parkway see active state-patrol activity. Cross-border purchase patterns with New York (adult-use legal, but slower retail rollout), Pennsylvania (medical only), and Delaware (adult-use as of 2025) continue to shape consumer flows.